Summit Global Investments Neurocrine Biosciences Inc Transaction History

Summit Global Investments

$1.6 Billion
Q4 2024

A detailed history of Summit Global Investments transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Summit Global Investments holds 32,060 shares of NBIX stock, worth $3.82 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

32,060

Previous 53,577 40.16%

Holding current value

$3.82 Million

Previous $6.17 Million 29.11%

% of portfolio

0.27%

Previous 0.39%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$111.62 - $139.44 $2.4 Million - $3 Million	-21,517 Reduced 40.16%	32,060 $4.38 Million
Q3 2024 Oct 31, 2024	SELL	$114.58 - $153.15 $2.75 Million - $3.68 Million	-24,024 Reduced 30.96%	53,577 $6.17 Million
Q2 2024 Jul 22, 2024	BUY	$130.86 - $143.19 $3.68 Million - $4.03 Million	28,124 Added 56.84%	77,601 $10.7 Million
Q1 2024 Apr 29, 2024	BUY	$130.4 - $143.74 $1.14 Million - $1.26 Million	8,744 Added 21.47%	49,477 $6.82 Million
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $1.13 Million - $1.42 Million	10,696 Added 35.61%	40,733 $5.37 Million
Q3 2023 Oct 13, 2023	BUY	$94.02 - $117.1 $38,172 - $47,542	406 Added 1.37%	30,037 $3.38 Million
Q2 2023 Jul 18, 2023	BUY	$89.53 - $104.87 $57,836 - $67,746	646 Added 2.23%	29,631 $2.79 Million
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $217,299 - $284,053	2,309 Added 8.66%	28,985 $2.93 Million
Q4 2022 Jan 31, 2023	BUY	$106.72 - $127.06 $1.6 Million - $1.9 Million	14,979 Added 128.06%	26,676 $3.19 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $1.08 Million - $1.26 Million	11,697 New	11,697 $1.24 Million

Others Institutions Holding NBIX

# of Institutions

654

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.

Account

Summit Global Investments Neurocrine Biosciences Inc Transaction History